Mylan merged with Pfizer's Upjohn division, which was part of Viatris, leading to volatility in the stocks of the involved companies.
13 reports, 3 independent
Updated Aug 31
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 13
- Developments
- 1
- Repetition
- 92%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Mylan merged with Pfizer's Upjohn division, which was part of Viatris, leading to volatility in the stocks of the involved companies.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- yahoo.com
- StockStory1 Volatile Stock on Our Buy List and 2 Facing Challenges Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during ris
- StockStoryGeneric Pharmaceuticals Stocks Q2 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Best of the Bunch Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stock
- StockStory3 Stocks Under $50 Walking a Fine Line Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, i
- StockStory3 Hyped Up Stocks That Fall Short Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new produc
- Pharmaceutical TechnologyEpiPen patent expiry opens new era for innovation The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market. Mylan acquired the
- StockStoryViatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 5.6% year on ye
- StockStory1 Mid-Cap Stock on Our Buy List and 2 We Avoid Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But th
- StockStory1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but
- StockStoryQ1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks The end of the earnings season is always a good time to take a step back and see who shined (and wh